<DOC>
	<DOC>NCT02426918</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy of 2 different doses of intravenous and oral Debio 1450 compared with intravenous vancomycin and oral linezolid in the treatment of patients with staphylococcal ABSSSI.</brief_summary>
	<brief_title>Study of Debio 1450 for Bacterial Skin Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Has clinically documented infection of the skin or skin structure suspected or documented to be caused by a staphylococcal pathogen Meets other protocolspecified criteria for qualification and contraception Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related to food, drink and medications Voluntarily consents to participate and provides written informed consent prior to any protocolspecific procedures Has history or current use of overthecounter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocolspecified parameters Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or wellbeing of the participant or study staff; 2. the safety or wellbeing of the participant's offspring (such as through pregnancy or breastfeeding); 3. the analysis of results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>